ImmuCell reports Q1 2026 preliminary sales up 28.4% to $10.4M; Tri-Shield up 38.5%

IMMUCELL CORP /DE/

2026-Q1 EPS reported $0.21 revenue$10,357,295

Total product sales $10.4M vs $8.1M in Q1 2025, a 28.4% increase.
Domestic sales $9.7M (+35.7%); international sales $0.6M (-30.2%).
Tri-Shield First Defense sales $7.9M (+38.5%); Dual-Force & Other $2.5M (+4.4%).
CFO notes prior backorder situation still complicates comparisons but operational progress shown.
Conference call scheduled for May 15, 2026 at 9:00 AM ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue $10.4 million.

Period: the quarter ended March 31, 2026
Revenue: $10.4 million
Result: preliminary results

Exact text from the filing

health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: ● Domestic sales were $9.7 million in 2026, a 35.7% increase

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-26-011757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.